Schaefer Niklaus, Prior John
CHUV, Service de médecine nucléaire et imagerie moléculaire, Université de Lausanne.
Ther Umsch. 2019 Sep;76(4):167-172. doi: 10.1024/0040-5930/a001080.
Nuclear medicine diagnostics, therapy and theranostics in the context of modern oncology Nuclear medicine deals with imaging, therapy and theranostics using radioactive elements bound to targeted carrier molecules, so-called radiotracers. Modern oncology in particular benefits from the increasing diagnostic possibilities, for example in the context of increasingly precise tumour spread diagnostics or the early measurement of tumour response under targeted therapies. Modern nuclear medicine also offers new and innovative methods for the treatment of special types of tumours. For example, new therapies are available to treat metastatic prostate cancer, while other methods, such as breast and lung cancer or pancreatic cancer, are currently being tested in clinical trials. Nuclear medicine is complemented by theranostics, which combines therapeutic and diagnostic methods. Particularly in modern, personalized oncology with all its targeted therapies, these methods benefit from predicting therapy and high response rates.
现代肿瘤学背景下的核医学诊断、治疗与诊疗一体化 核医学利用与靶向载体分子结合的放射性元素（即所谓的放射性示踪剂）进行成像、治疗和诊疗一体化。现代肿瘤学尤其受益于不断增加的诊断可能性，例如在日益精确的肿瘤扩散诊断或靶向治疗下肿瘤反应的早期测量方面。现代核医学还为特殊类型肿瘤的治疗提供了新的创新方法。例如，有新的疗法可用于治疗转移性前列腺癌，而其他方法，如乳腺癌、肺癌或胰腺癌的治疗方法目前正在临床试验中进行测试。核医学通过诊疗一体化得到补充，诊疗一体化将治疗和诊断方法结合起来。特别是在现代个性化肿瘤学及其所有靶向治疗中，这些方法受益于治疗预测和高反应率。
